KRTX - Karuna Therapeutics reports KarXT results from Phase 1b study in healthy elderly volunteers

Karuna Therapeutics (KRTX) announces data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers.The Company had previously announced a preliminary analysis from the first two cohorts in the trial earlier this year.Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 trial in adults with schizophrenia while maintaining a favorable tolerability profile.The majority of healthy elderly volunteers in the Phase 1b trial were titrated to xanomeline doses of 150 to 200 mg when dosed with KarXT. Safety and tolerability profile in Phase 1b trial in healthy elderly volunteers consistent with prior trials of KarXT.Based Phase 1b results, trial, the Company plans to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in H1 2022.

For further details see:

Karuna Therapeutics reports KarXT results from Phase 1b study in healthy elderly volunteers